PAEDIATRIC ARV PROCUREMENT WORKING GROUP

ROAD AHEAD & IMPROVED ENGAGEMENT

- Active engagement with countries and partners to adopt/transition to the prescribed IATT formulary to guide selection and procurement of paediatric ARVs around a subset of optimal products
- Forecasts communicated to WHO/AMDS with anticipated orders by the Procurement Consortium members
- Ongoing monitoring of market challenges and continued engagement with Suppliers to manage exits, transitions, bottlenecks, etc.
- Implementation of reporting indicators to track PAPWG progress
- Development of communication tools and procurement analytics to support coordination efforts at country & global levels as well as interaction with the pediatric HIV initiatives
Established Quarterly Consolidated Order Cycles

<table>
<thead>
<tr>
<th>Quarter, Year</th>
<th>Orders Placed with Manufacturers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2015</td>
<td>April 3\textsuperscript{rd} 2015</td>
</tr>
<tr>
<td>Q2 2015</td>
<td>July 3\textsuperscript{th} 2015</td>
</tr>
<tr>
<td>Q3 2015</td>
<td>October 2\textsuperscript{nd} 2015</td>
</tr>
<tr>
<td>Q4 2015</td>
<td>December 21\textsuperscript{st} 2015</td>
</tr>
</tbody>
</table>

Upcoming order cycle deadlines
Procurement Consortium Reporting Point Indicators

1. Supply Security
   A. Average lead time for the Procurement Consortium member orders $^{SA}$
   B. Average delay in delivery for Procurement Consortium member orders $^{SA}$
   C. % of delayed deliveries for Procurement Consortium member orders $^{SA}$

2. Consolidated Order Management
   A. % of tracked products with validated batch sizes information
   B. % of products able to complete a full batch for PC $^A$

3. Anticipated Demand
   A. Volume of ARVs procured by the Procurement Consortium $^A$
   B. Value of ARVs procured by the Procurement Consortium $^A$
   C. % of products in quarterly order cycle where orders are in line with anticipated demand forecast $^Q$

●Completed  Q – Quarterly  SA – Semi-Annual  A – Annual
Procurement Consortium Reporting Point Indicators

4.  Product Selection and Optimization
  A.  # of countries procuring optimal and limited-use ARVs exclusively (as part of the Procurement Consortium) SA
  B.  # of countries that have transitioned from non-essential to optimal ARVs (as part of the Procurement Consortium) A

5.  PAPWG Reach
  A.  # of children reached by the Procurement Consortium A
  B.  # of countries part of the Procurement Consortium A
  C.  # of countries outside of the Procurement Consortium that are using the designated ordering cycle dates A

● Completed    Q – Quarterly    SA – Semi-Annual    A – Annual
3a. Demand 2014

Volume of ARVs procured by the Procurement Consortium

- **Optimal**: 9.5M (90%)
- **Limited-Use**: 900,000 (8%)
- **Non-Essential**: 200,000 (2%)

Total: 10.6 million packs
3b. Demand 2014
Value of ARVs procured by the Procurement Consortium

Total $35.8 million

- Optimal: $32.3M (90%)
- Limited-Use: $400K (1%)
- Non-Essential: $3.1M (9%)

$32.3M 90%
$3.1M 9%
$400K 1%
Total $35.8 million
5b. PAPWG Reach

# of countries part of the Procurement Consortium

2013: 65
2014: 75